In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

So far, benefits associated with consistent GLP-1 use in curbing medical spending lack sufficient data-backed evidence. It’s ...

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

The hype started when celebrities were rumored to be using drugs like Wegovy off-label for aesthetic weight loss. Cue the ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...